MEDICAL SERVICES

CERTIFICATIONS

  • American Board of Psychiatry and Neurology, Psychiatry
  • American Board of Psychiatry and Neurology, Child and Adolescent Psychiatry

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Reus VI, Fochtmann LJ, Bukstein O, Eyler AE, Hilty DM, Horvitz-Lennon M, Mahoney J, Pasic J, Weaver M, Wills CD, McIntyre J, Kidd J, Yager J, Hong SH. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder. Am J Psychiatry. 2018 01 01; 175(1):86-90. View abstract
  2. Barterian JA, Arnold LE, Brown NV, Farmer CA, Williams C, Findling RL, Kolko DJ, Bukstein OG, Molina BSG, Townsend L, Aman MG. Clinical Implications From the Treatment of Severe Childhood Aggression (TOSCA) Study: A Re-Analysis and Integration of Findings. J Am Acad Child Adolesc Psychiatry. 2017 Dec; 56(12):1026-1033. View abstract
  3. Walter HJ, Bukstein OG. Forward to the Future: Clinical Updates and Clinical Practice Guidelines. J Am Acad Child Adolesc Psychiatry. 2017 Oct; 56(10):811-812. View abstract
  4. Bukstein OG. Challenges and Gaps in Understanding Substance Use Problems in Transitional Age Youth. Child Adolesc Psychiatr Clin N Am. 2017 04; 26(2):253-269. View abstract
  5. Tamm L, Denton CA, Epstein JN, Schatschneider C, Taylor H, Arnold LE, Bukstein O, Anixt J, Koshy A, Newman NC, Maltinsky J, Brinson P, Loren REA, Prasad MR, Ewing-Cobbs L, Vaughn A. Comparing treatments for children with ADHD and word reading difficulties: A randomized clinical trial. J Consult Clin Psychol. 2017 May; 85(5):434-446. View abstract
  6. Findling RL, Townsend L, Brown NV, Arnold LE, Gadow KD, Kolko DJ, McNamara NK, Gary DS, Kaplin DB, Farmer CA, Kipp H, Williams C, Butter EM, Bukstein OG, Rice R, Buchan-Page K, Molina BS, Aman MG. The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders. J Child Adolesc Psychopharmacol. 2017 02; 27(1):52-65. View abstract
  7. Pelham WE, Gnagy EM, Sibley MH, Kipp HL, Smith BH, Evans SW, Bukstein O. Attributions and Perception of Methylphenidate Effects in Adolescents With ADHD. J Atten Disord. 2017 01; 21(2):129-136. View abstract
  8. Pelham WE, Meichenbaum DL, Smith BH, Sibley MH, Gnagy EM, Bukstein O. Acute Effects of MPH on the Parent-Teen Interactions of Adolescents With ADHD. J Atten Disord. 2017 01; 21(2):158-167. View abstract
  9. Pelham WE, Smith BH, Evans SW, Bukstein O, Gnagy EM, Greiner AR, Sibley MH. The Effectiveness of Short- and Long-Acting Stimulant Medications for Adolescents With ADHD in a Naturalistic Secondary School Setting. J Atten Disord. 2017 01; 21(1):40-45. View abstract
  10. Farmer CA, Epstein JN, Findling RL, Gadow KD, Arnold LE, Kipp H, Kolko DJ, Butter E, Schneider J, Bukstein OG, McNamara NK, Molina BS, Aman MG. Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory. J Child Adolesc Psychopharmacol. 2017 03; 27(2):117-124. View abstract
  11. Gadow KD, Brown NV, Arnold LE, Buchan-Page KA, Bukstein OG, Butter E, Farmer CA, Findling RL, Kolko DJ, Molina BS, Rice RR, Schneider J, Aman MG. Severely Aggressive Children Receiving Stimulant Medication Versus Stimulant and Risperidone: 12-Month Follow-Up of the TOSCA Trial. J Am Acad Child Adolesc Psychiatry. 2016 06; 55(6):469-78. View abstract
  12. Arnold LE, Gadow KD, Farmer CA, Findling RL, Bukstein O, Molina BS, Brown NV, Li X, Rundberg-Rivera EV, Bangalore S, Buchan-Page K, Hurt EA, Rice R, McNamara NK, Aman MG. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response. J Child Adolesc Psychopharmacol. 2015 Apr; 25(3):203-12. View abstract
  13. Farmer CA, Brown NV, Gadow KD, Arnold LE, Kolko DG, Findling RL, Molina BS, Buchan-Page KA, Rice RR, Bangalore SS, Bukstein O, Rundberg-Rivera EV, McNamara N, Aman MG. Comorbid symptomatology moderates response to risperidone, stimulant, and parent training in children with severe aggression, disruptive behavior disorder, and attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2015 Apr; 25(3):213-24. View abstract
  14. Rundberg-Rivera EV, Townsend LD, Schneider J, Farmer CA, Molina BB, Findling RL, Gadow KD, Bukstein OG, Arnold LE, Kolko DJ, Buchan-Page KA, McNamara NK, Michel C, Austin A, Kipp H, Rice RR, Aman MG. Participant satisfaction in a study of stimulant, parent training, and risperidone in children with severe physical aggression. J Child Adolesc Psychopharmacol. 2015 Apr; 25(3):225-33. View abstract
  15. Kaat A, Farmer C, Gadow K, Findling RL, Bukstein O, Arnold LE, Bangalore S, McNamara N, Aman M. Factor Validity of a Proactive and Reactive Aggression Rating Scale. J Child Fam Stud. 2015 Sep 01; 24(9):2734-2744. View abstract
  16. Cutler AJ, Brams M, Bukstein O, Mattingly G, McBurnett K, White C, Rubin J. Response/remission with guanfacine extended-release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2014 Oct; 53(10):1092-101. View abstract
  17. Gadow KD, Arnold LE, Molina BS, Findling RL, Bukstein OG, Brown NV, McNamara NK, Rundberg-Rivera EV, Li X, Kipp HL, Schneider J, Farmer CA, Baker JL, Sprafkin J, Rice RR, Bangalore SS, Butter EM, Buchan-Page KA, Hurt EA, Austin AB, Grondhuis SN, Aman MG. Risperidone added to parent training and stimulant medication: effects on attention-deficit/hyperactivity disorder, oppositional defiant disorder, conduct disorder, and peer aggression. J Am Acad Child Adolesc Psychiatry. 2014 Sep; 53(9):948-959.e1. View abstract
  18. Goldstein BI, Goldstein TR, Collinger KA, Axelson DA, Bukstein OG, Birmaher B, Miklowitz DJ. Treatment development and feasibility study of family-focused treatment for adolescents with bipolar disorder and comorbid substance use disorders. J Psychiatr Pract. 2014 May; 20(3):237-48. View abstract
  19. Kolko DJ, Lindhiem O, Hart J, Bukstein OG. Evaluation of a booster intervention three years after acute treatment for early-onset disruptive behavior disorders. J Abnorm Child Psychol. 2014; 42(3):383-98. View abstract
  20. Aman MG, Bukstein OG, Gadow KD, Arnold LE, Molina BS, McNamara NK, Rundberg-Rivera EV, Li X, Kipp H, Schneider J, Butter EM, Baker J, Sprafkin J, Rice RR, Bangalore SS, Farmer CA, Austin AB, Buchan-Page KA, Brown NV, Hurt EA, Grondhuis SN, Findling RL. What does risperidone add to parent training and stimulant for severe aggression in child attention-deficit/hyperactivity disorder? J Am Acad Child Adolesc Psychiatry. 2014 Jan; 53(1):47-60.e1. View abstract
  21. Bukstein OG. Personality-targeted interventions delivered by teachers may be effective at reducing alcohol use. Evid Based Ment Health. 2013 Nov; 16(4):100. View abstract
  22. Pearson DA, Santos CW, Aman MG, Arnold LE, Casat CD, Mansour R, Lane DM, Loveland KA, Bukstein OG, Jerger SW, Factor P, Vanwoerden S, Perez E, Cleveland LA. Effects of extended release methylphenidate treatment on ratings of attention-deficit/hyperactivity disorder (ADHD) and associated behavior in children with autism spectrum disorders and ADHD symptoms. J Child Adolesc Psychopharmacol. 2013 Jun; 23(5):337-51. View abstract
  23. Bukstein OG, Head J. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder. Expert Opin Pharmacother. 2012 Oct; 13(15):2207-13. View abstract
  24. Bukstein OG. Taking note of over-the-counter remedies for adolescents with cannabis dependence. Am J Psychiatry. 2012 Aug; 169(8):771-3. View abstract
  25. Bukstein OG. Attention deficit hyperactivity disorder and substance use disorders. Curr Top Behav Neurosci. 2012; 9:145-72. View abstract
  26. Shenk CE, Dorn LD, Kolko DJ, Susman EJ, Noll JG, Bukstein OG. Predicting Treatment Response for Oppositional Defiant and Conduct Disorder Using Pre-treatment Adrenal and Gonadal Hormones. J Child Fam Stud. 2012 Dec; 21(6):973-981. View abstract
  27. Kraus LJ, Thomas CR, Bukstein OG, Walter HJ, Benson RS, Chrisman A, Farchione TR, Hamilton J, Keable H, Kinlan J, Schoettle U, Siegel M, Stock S, Ptakowski KK, Medicus J. Practice parameter for child and adolescent forensic evaluations. J Am Acad Child Adolesc Psychiatry. 2011 Dec; 50(12):1299-312. View abstract
  28. Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, Lyne A, Grannis K, Youcha S. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012 Jan; 51(1):74-85.e2. View abstract
  29. Farmer CA, Arnold LE, Bukstein OG, Findling RL, Gadow KD, Li X, Butter EM, Aman MG. The treatment of severe child aggression (TOSCA) study: Design challenges. Child Adolesc Psychiatry Ment Health. 2011 Nov 10; 5(1):36. View abstract
  30. Cornelius JR, Douaihy A, Bukstein OG, Daley DC, Wood SD, Kelly TM, Salloum IM. Evaluation of cognitive behavioral therapy/motivational enhancement therapy (CBT/MET) in a treatment trial of comorbid MDD/AUD adolescents. Addict Behav. 2011 Aug; 36(8):843-8. View abstract
  31. Demidovich M, Kolko DJ, Bukstein OG, Hart J. Medication refusal in children with oppositional defiant disorder or conduct disorder and comorbid attention-deficit/hyperactivity disorder: medication history and clinical correlates. J Child Adolesc Psychopharmacol. 2011 Feb; 21(1):57-66. View abstract
  32. Dorn LD, Kolko DJ, Shenk CE, Susman EJ, Bukstein O. Influence of treatment for disruptive behavior disorders on adrenal and gonadal hormones in youth. J Clin Child Adolesc Psychol. 2011; 40(4):562-71. View abstract
  33. Bukstein OG. Clinical practice guidelines for attention-deficit/hyperactivity disorder: a review. Postgrad Med. 2010 Sep; 122(5):69-77. View abstract
  34. Bukstein OG, Horner MS. Management of the adolescent with substance use disorders and comorbid psychopathology. Child Adolesc Psychiatr Clin N Am. 2010 Jul; 19(3):609-23. View abstract
  35. Cornelius JR, Bukstein OG, Douaihy AB, Clark DB, Chung TA, Daley DC, Wood DS, Brown SJ. Double-blind fluoxetine trial in comorbid MDD-CUD youth and young adults. Drug Alcohol Depend. 2010 Nov 01; 112(1-2):39-45. View abstract
  36. Cohen JA, Bukstein O, Walter H, Benson SR, Chrisman A, Farchione TR, Hamilton J, Keable H, Kinlan J, Schoettle U, Siegel M, Stock S, Medicus J. Practice parameter for the assessment and treatment of children and adolescents with posttraumatic stress disorder. J Am Acad Child Adolesc Psychiatry. 2010 Apr; 49(4):414-30. View abstract
  37. Arnold LE, Bozzolo DR, Hodgkins P, McKay M, Beckett-Thurman L, Greenbaum M, Bukstein O, Patel A. Switching from oral extended-release methylphenidate to the methylphenidate transdermal system: continued attention-deficit/hyperactivity disorder symptom control and tolerability after abrupt conversion. Curr Med Res Opin. 2010 Jan; 26(1):129-37. View abstract
  38. Bukstein OG, Arnold LE, Landgraf JM, Hodgkins P. Does switching from oral extended-release methylphenidate to the methylphenidate transdermal system affect health-related quality-of-life and medication satisfaction for children with attention-deficit/hyperactivity disorder? Child Adolesc Psychiatry Ment Health. 2009 Dec 10; 3(1):39. View abstract
  39. Goldstein BI, Bukstein OG. Comorbid substance use disorders among youth with bipolar disorder: opportunities for early identification and prevention. J Clin Psychiatry. 2010 Mar; 71(3):348-58. View abstract
  40. Cannon M, Pelham WH, Sallee FR, Palumbo DR, Bukstein O, Daviss WB. Effects of clonidine and methylphenidate on family quality of life in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009 Oct; 19(5):511-7. View abstract
  41. Brent DA, Greenhill LL, Compton S, Emslie G, Wells K, Walkup JT, Vitiello B, Bukstein O, Stanley B, Posner K, Kennard BD, Cwik MF, Wagner A, Coffey B, March JS, Riddle M, Goldstein T, Curry J, Barnett S, Capasso L, Zelazny J, Hughes J, Shen S, Gugga SS, Turner JB. The Treatment of Adolescent Suicide Attempters study (TASA): predictors of suicidal events in an open treatment trial. J Am Acad Child Adolesc Psychiatry. 2009 Oct; 48(10):987-96. View abstract
  42. Vitiello B, Brent DA, Greenhill LL, Emslie G, Wells K, Walkup JT, Stanley B, Bukstein O, Kennard BD, Compton S, Coffey B, Cwik MF, Posner K, Wagner A, March JS, Riddle M, Goldstein T, Curry J, Capasso L, Mayes T, Shen S, Gugga SS, Turner JB, Barnett S, Zelazny J. Depressive symptoms and clinical status during the Treatment of Adolescent Suicide Attempters (TASA) Study. J Am Acad Child Adolesc Psychiatry. 2009 Oct; 48(10):997-1004. View abstract
  43. Findling RL, Wigal SB, Bukstein OG, Boellner SW, Abikoff HB, Turnbow JM, Civil R. Long-term tolerability of the methylphenidate transdermal system in pediatric attention-deficit/hyperactivity disorder: a multicenter, prospective, 12-month, open-label, uncontrolled, phase III extension of four clinical trials. Clin Ther. 2009 Aug; 31(8):1844-55. View abstract
  44. Kolko DJ, Dorn LD, Bukstein OG, Pardini D, Holden EA, Hart J. Community vs. clinic-based modular treatment of children with early-onset ODD or CD: a clinical trial with 3-year follow-up. J Abnorm Child Psychol. 2009 Jul; 37(5):591-609. View abstract
  45. Bukstein O. Substance use disorders and ADHD. CNS Spectr. 2009 Jul; 14(7 Suppl 6):10-1; discussion 13-4. View abstract
  46. Bukstein OG. Transdermal methylphenidate system: old wine in a new bottle. Expert Opin Drug Metab Toxicol. 2009 Jun; 5(6):661-5. View abstract
  47. Kelly TM, Donovan JE, Chung T, Bukstein OG, Cornelius JR. Brief screens for detecting alcohol use disorder among 18-20 year old young adults in emergency departments: Comparing AUDIT-C, CRAFFT, RAPS4-QF, FAST, RUFT-Cut, and DSM-IV 2-Item Scale. Addict Behav. 2009 Aug; 34(8):668-74. View abstract
  48. Cornelius JR, Bukstein OG, Wood DS, Kirisci L, Douaihy A, Clark DB. Double-blind placebo-controlled trial of fluoxetine in adolescents with comorbid major depression and an alcohol use disorder. Addict Behav. 2009 Oct; 34(10):905-9. View abstract
  49. DeMaso DR, Martini DR, Cahen LA, Bukstein O, Walter HJ, Benson S, Chrisman A, Farchione T, Hamilton J, Keable H, Kinlan J, Schoettle U, Siegel M, Stock S, Ptakowski KK, Medicus J. Practice parameter for the psychiatric assessment and management of physically ill children and adolescents. J Am Acad Child Adolesc Psychiatry. 2009 Feb; 48(2):213-33. View abstract
  50. Dorn LD, Kolko DJ, Susman EJ, Huang B, Stein H, Music E, Bukstein OG. Salivary gonadal and adrenal hormone differences in boys and girls with and without disruptive behavior disorders: Contextual variants. Biol Psychol. 2009 Apr; 81(1):31-9. View abstract
  51. Stanley JA, Kipp H, Greisenegger E, MacMaster FP, Panchalingam K, Keshavan MS, Bukstein OG, Pettegrew JW. Evidence of developmental alterations in cortical and subcortical regions of children with attention-deficit/hyperactivity disorder: a multivoxel in vivo phosphorus 31 spectroscopy study. Arch Gen Psychiatry. 2008 Dec; 65(12):1419-28. View abstract
  52. Bukstein O. Substance use disorders in adolescents with attention-deficit/hyperactivity disorder. Adolesc Med State Art Rev. 2008 Aug; 19(2):242-53, viii. View abstract
  53. Faraone SV, Glatt SJ, Bukstein OG, Lopez FA, Arnold LE, Findling RL. Effects of once-daily oral and transdermal methylphenidate on sleep behavior of children with ADHD. J Atten Disord. 2009 Jan; 12(4):308-15. View abstract
  54. Szobot CM, Bukstein O. Attention deficit hyperactivity disorder and substance use disorders. Child Adolesc Psychiatr Clin N Am. 2008 Apr; 17(2):309-23, viii. View abstract
  55. Marshal MP, Friedman MS, Stall R, King KM, Miles J, Gold MA, Bukstein OG, Morse JQ. Sexual orientation and adolescent substance use: a meta-analysis and methodological review. Addiction. 2008 Apr; 103(4):546-56. View abstract
  56. Szobot CM, Rohde LA, Katz B, Ruaro P, Schaefer T, Walcher M, Bukstein O, Pechansky F. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder. Braz J Med Biol Res. 2008 Mar; 41(3):250-7. View abstract
  57. Palumbo DR, Sallee FR, Pelham WE, Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008 Feb; 47(2):180-8. View abstract
  58. Daviss WB, Patel NC, Robb AS, McDermott MP, Bukstein OG, Pelham WE, Palumbo D, Harris P, Sallee FR. Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008 Feb; 47(2):189-98. View abstract
  59. Bukstein O. Substance abuse in patients with attention-deficit/hyperactivity disorder. Medscape J Med. 2008 Jan 31; 10(1):24. View abstract
  60. Molina BS, Flory K, Bukstein OG, Greiner AR, Baker JL, Krug V, Evans SW. Feasibility and preliminary efficacy of an after-school program for middle schoolers with ADHD: a randomized trial in a large public middle school. J Atten Disord. 2008 Nov; 12(3):207-17. View abstract
  61. Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008 Jan; 69(1):149-59. View abstract
  62. Birmaher B, Brent D, Bernet W, Bukstein O, Walter H, Benson RS, Chrisman A, Farchione T, Greenhill L, Hamilton J, Keable H, Kinlan J, Schoettle U, Stock S, Ptakowski KK, Medicus J. Practice parameter for the assessment and treatment of children and adolescents with depressive disorders. J Am Acad Child Adolesc Psychiatry. 2007 Nov; 46(11):1503-26. View abstract
  63. Manos MJ, Tom-Revzon C, Bukstein OG, Crismon ML. Changes and challenges: managing ADHD in a fast-paced world. J Manag Care Pharm. 2007 Nov; 13(9 Suppl B):S2-S13; quiz S14-S16. View abstract
  64. March JS, Szatmari P, Bukstein O, Chrisman A, Kondo D, Hamilton JD, Kremer CM, Kratochvil CJ. AACAP 2005 Research Forum: speeding the adoption of evidence-based practice in pediatric psychiatry. J Am Acad Child Adolesc Psychiatry. 2007 Sep; 46(9):1098-110. View abstract
  65. Szobot CM, Rohde LA, Bukstein O, Molina BS, Martins C, Ruaro P, Pechansky F. Is attention-deficit/hyperactivity disorder associated with illicit substance use disorders in male adolescents? A community-based case-control study. Addiction. 2007 Jul; 102(7):1122-30. View abstract
  66. Stanley JA, Kipp H, Greisenegger E, MacMaster FP, Panchalingam K, Pettegrew JW, Keshavan MS, Bukstein OG. Regionally specific alterations in membrane phospholipids in children with ADHD: An in vivo 31P spectroscopy study. Psychiatry Res. 2006 Dec 01; 148(2-3):217-21. View abstract
  67. McGough JJ, McBurnett K, Bukstein O, Wilens TE, Greenhill L, Lerner M, Stein M. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2006 Jun; 16(3):351-6. View abstract
  68. Bukstein OG. Therapeutic challenges of attention-deficit hyperactivity disorder with substance use disorders. Expert Rev Neurother. 2006 Apr; 6(4):541-9. View abstract
  69. Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2006 Jan; 160(1):82-90. View abstract
  70. Bukstein OG, Cornelius J, Trunzo AC, Kelly TM, Wood DS. Clinical predictors of treatment in a population of adolescents with alcohol use disorders. Addict Behav. 2005 Oct; 30(9):1663-73. View abstract
  71. Kelly TM, Donovan JE, Cornelius JR, Bukstein OG, Delbridge TR, Kinnane JM. Alcohol use disorder symptoms and risk-taking behavior as predictors of alcohol-related medical events among young adults treated in emergency departments. Addict Behav. 2005 Oct; 30(9):1674-89. View abstract
  72. Cornelius JR, Clark DB, Bukstein OG, Birmaher B, Salloum IM, Brown SA. Acute phase and five-year follow-up study of fluoxetine in adolescents with major depression and a comorbid substance use disorder: a review. Addict Behav. 2005 Oct; 30(9):1824-33. View abstract
  73. Bukstein OG, Bernet W, Arnold V, Beitchman J, Shaw J, Benson RS, Kinlan J, McClellan J, Stock S, Ptakowski KK. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. J Am Acad Child Adolesc Psychiatry. 2005 Jun; 44(6):609-21. View abstract
  74. Cornelius JR, Clark DB, Bukstein OG, Kelly TM, Salloum IM, Wood DS. Fluoxetine in adolescents with comorbid major depression and an alcohol use disorder: a 3-year follow-up study. Addict Behav. 2005 May; 30(4):807-14. View abstract
  75. Chacko A, Pelham WE, Gnagy EM, Greiner A, Vallano G, Bukstein O, Rancurello M. Stimulant medication effects in a summer treatment program among young children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2005 Mar; 44(3):249-57. View abstract
  76. Bukstein OG, Trunzo AC. Alcohol use disorder in adolescents. Minerva Pediatr. 2005 Feb; 57(1):7-20. View abstract
  77. Cornelius JR, Clark DB, Bukstein OG, Salloum IM. Treatment of co-occurring alcohol, drug, and psychiatric disorders. Recent Dev Alcohol. 2005; 17:349-65. View abstract
  78. Fritz G, Rockney R, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, Kroeger Ptakowski K. Practice parameter for the assessment and treatment of children and adolescents with enuresis. J Am Acad Child Adolesc Psychiatry. 2004 Dec; 43(12):1540-50. View abstract
  79. Ghaziuddin N, Kutcher SP, Knapp P, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, Kroeger Ptakowski K. Practice parameter for use of electroconvulsive therapy with adolescents. J Am Acad Child Adolesc Psychiatry. 2004 Dec; 43(12):1521-39. View abstract
  80. Bukstein OG, Winters K. Salient variables for treatment research of adolescent alcohol and other substance use disorders. Addiction. 2004 Nov; 99 Suppl 2:23-37. View abstract
  81. Cornelius JR, Maisto SA, Martin CS, Bukstein OG, Salloum IM, Daley DC, Wood DS, Clark DB. Major depression associated with earlier alcohol relapse in treated teens with AUD. Addict Behav. 2004 Jul; 29(5):1035-8. View abstract
  82. Bukstein OG. Satisfaction with treatment for attention-deficit/hyperactivity disorder. Am J Manag Care. 2004 Jul; 10(4 Suppl):S107-16. View abstract
  83. Cornelius JR, Clark DB, Salloum IM, Bukstein OG, Kelly TM. Interventions in suicidal alcoholics. Alcohol Clin Exp Res. 2004 May; 28(5 Suppl):89S-96S. View abstract
  84. Cornelius JR, Bukstein OG, Salloum IM, Kelly TM, Wood DS, Clark DB. Fluoxetine in depressed AUD adolescents: a 1-year follow-up evaluation. J Child Adolesc Psychopharmacol. 2004; 14(1):33-8. View abstract
  85. Clark DB, Wood DS, Cornelius JR, Bukstein OG, Martin CS. Clinical practices in the pharmacological treatment of comorbid psychopathology in adolescents with alcohol use disorders. J Subst Abuse Treat. 2003 Dec; 25(4):293-5. View abstract
  86. Kelly TM, Donovan JE, Cornelius JR, Bukstein OG, Delbridge TR, Clark DB. Psychiatric disorders among older adolescents treated in emergency departments on weekends: a comparison with a matched community sample. J Stud Alcohol. 2003 Sep; 64(5):616-22. View abstract
  87. Bukstein OG. Once-daily atomoxetine may reduce attention deficit hyperactivity disorder symptoms in children and adolescents. Evid Based Ment Health. 2003 May; 6(2):42. View abstract
  88. Cornelius JR, Bukstein O, Salloum I, Clark D. Alcohol and psychiatric comorbidity. Recent Dev Alcohol. 2003; 16:361-74. View abstract
  89. Molina BS, Bukstein OG, Lynch KG. Attention-deficit/hyperactivity disorder and conduct disorder symptomatology in adolescents with alcohol use disorder. Psychol Addict Behav. 2002 Jun; 16(2):161-4. View abstract
  90. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2002 Feb; 41(2 Suppl):26S-49S. View abstract
  91. Masters KJ, Bellonci C, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S. Practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions, with special reference to seclusion and restraint. J Am Acad Child Adolesc Psychiatry. 2002 Feb; 41(2 Suppl):4S-25S. View abstract
  92. Clark DB, Bukstein O, Cornelius J. Alcohol use disorders in adolescents: epidemiology, diagnosis, psychosocial interventions, and pharmacological treatment. Paediatr Drugs. 2002; 4(8):493-502. View abstract
  93. Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, Benson RS, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, Kroeger K. Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2001 Nov; 40(11):1352-5. View abstract
  94. Masters KJ, Bellonci C, Bernet W, Arnold V, Beitchman J, Benson S, Bukstein O, Kinlan J, McClellan J, Rue D, Shaw JA, Stock S, Kroeger K. Summary of the practice parameter for the prevention and management of aggressive behavior in child and adolescent psychiatric institutions with special reference to seclusion and restraint. J Am Acad Child Adolesc Psychiatry. 2001 Nov; 40(11):1356-8. View abstract
  95. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G. Randomized, controlled trial of oros methylphenidate once a day in children with attention-deficit/hyperactivity disorder. Pediatrics. 2001 Oct; 108(4):883-92. View abstract
  96. Cornelius JR, Bukstein OG, Birmaher B, Salloum IM, Lynch K, Pollock NK, Gershon S, Clark D. Fluoxetine in adolescents with major depression and an alcohol use disorder: an open-label trial. Addict Behav. 2001 Sep-Oct; 26(5):735-9. View abstract
  97. Evans SW, Pelham WE, Smith BH, Bukstein O, Gnagy EM, Greiner AR, Altenderfer L, Baron-Myak C. Dose-response effects of methylphenidate on ecologically valid measures of academic performance and classroom behavior in adolescents with ADHD. Exp Clin Psychopharmacol. 2001 May; 9(2):163-75. View abstract
  98. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T. Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry. 2001 Feb; 40(2):180-7. View abstract
  99. Vitiello B, Severe JB, Greenhill LL, Arnold LE, Abikoff HB, Bukstein OG, Elliott GR, Hechtman L, Jensen PS, Hinshaw SP, March JS, Newcorn JH, Swanson JM, Cantwell DP. Methylphenidate dosage for children with ADHD over time under controlled conditions: lessons from the MTA. J Am Acad Child Adolesc Psychiatry. 2001 Feb; 40(2):188-96. View abstract
  100. Pelham WE, Gnagy EM, Greiner AR, Hoza B, Hinshaw SP, Swanson JM, Simpson S, Shapiro C, Bukstein O, Baron-Myak C, McBurnett K. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. J Abnorm Child Psychol. 2000 Dec; 28(6):507-25. View abstract
  101. Martin CS, Pollock NK, Bukstein OG, Lynch KG. Inter-rater reliability of the SCID alcohol and substance use disorders section among adolescents. Drug Alcohol Depend. 2000 May 01; 59(2):173-6. View abstract
  102. Bukstein OG. Disruptive behavior disorders and substance use disorders in adolescents. J Psychoactive Drugs. 2000 Jan-Mar; 32(1):67-79. View abstract
  103. Kolko DJ, Bukstein OG, Barron J. Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings. J Am Acad Child Adolesc Psychiatry. 1999 May; 38(5):578-86. View abstract
  104. Bukstein OG, Kolko DJ. Effects of methylphenidate on aggressive urban children with attention deficit hyperactivity disorder. J Clin Child Psychol. 1998 Oct; 27(3):340-51. View abstract
  105. Smith BH, Pelham WE, Evans S, Gnagy E, Molina B, Bukstein O, Greiner A, Myak C, Presnell M, Willoughby M. Dosage effects of methylphenidate on the social behavior of adolescents diagnosed with attention-deficit hyperactivity disorder. Exp Clin Psychopharmacol. 1998 May; 6(2):187-204. View abstract
  106. Clark DB, Bukstein OG. Psychopathology in adolescent alcohol abuse and dependence. Alcohol Health Res World. 1998; 22(2):117-21, 126. View abstract
  107. Bukstein O. Practice parameters for the assessment and treatment of children and adolescents with substance use disorders. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997 Oct; 36(10 Suppl):140S-56S. View abstract
  108. Clark DB, Pollock N, Bukstein OG, Mezzich AC, Bromberger JT, Donovan JE. Gender and comorbid psychopathology in adolescents with alcohol dependence. J Am Acad Child Adolesc Psychiatry. 1997 Sep; 36(9):1195-203. View abstract
  109. Clark DB, Bukstein OG, Smith MG, Kaczynski NA, Mezzich AC, Donovan JE. Identifying anxiety disorders in adolescents hospitalized for alcohol abuse or dependence. Psychiatr Serv. 1995 Jun; 46(6):618-20. View abstract
  110. Arria AM, Dohey MA, Mezzich AC, Bukstein OG, Van Thiel DH. Self-reported health problems and physical symptomatology in adolescent alcohol abusers. J Adolesc Health. 1995 Mar; 16(3):226-31. View abstract
  111. Messer SC, Kempton T, Van Hasselt VB, Null JA, Bukstein OG. Cognitive distortions and adolescent affective disorder. Validity of the CNCEQ in an inpatient sample. Children's Negative Cognitive Error Questionnaire. Behav Modif. 1994 Jul; 18(3):339-51. View abstract
  112. Leonard HL, Topol D, Bukstein O, Hindmarsh D, Allen AJ, Swedo SE. Clonazepam as an augmenting agent in the treatment of childhood-onset obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 1994 Jul-Aug; 33(6):792-4. View abstract
  113. Kempton T, van Hasselt VB, Bukstein OG, Null JA. Cognitive distortions and psychiatric diagnosis in dually diagnosed adolescents. J Am Acad Child Adolesc Psychiatry. 1994 Feb; 33(2):217-22. View abstract
  114. Bukstein OG, Brent DA, Perper JA, Moritz G, Baugher M, Schweers J, Roth C, Balach L. Risk factors for completed suicide among adolescents with a lifetime history of substance abuse: a case-control study. Acta Psychiatr Scand. 1993 Dec; 88(6):403-8. View abstract
  115. Van Hasselt VB, Hersen M, Null JA, Ammerman RT, Bukstein OG, McGillivray J, Hunter A. Drug abuse prevention for high-risk African American children and their families: a review and model program. Addict Behav. 1993 Mar-Apr; 18(2):213-34. View abstract
  116. Van Hasselt VB, Null JA, Kempton T, Bukstein OG. Social skills and depression in adolescent substance abusers. Addict Behav. 1993 Jan-Feb; 18(1):9-18. View abstract
  117. Martin CS, Arria AM, Mezzich AC, Bukstein OG. Patterns of polydrug use in adolescent alcohol abusers. Am J Drug Alcohol Abuse. 1993; 19(4):511-21. View abstract
  118. Kaminer Y, Tarter RE, Bukstein OG, Kabene M. Comparison between treatment completers and noncompleters among dually diagnosed substance-abusing adolescents. J Am Acad Child Adolesc Psychiatry. 1992 Nov; 31(6):1046-9. View abstract
  119. Bukstein OG, Glancy LJ, Kaminer Y. Patterns of affective comorbidity in a clinical population of dually diagnosed adolescent substance abusers. J Am Acad Child Adolesc Psychiatry. 1992 Nov; 31(6):1041-5. View abstract
  120. Van Hasselt VB, Ammerman RT, Glancy LJ, Bukstein OG. Maltreatment in psychiatrically hospitalized dually diagnosed adolescent substance abusers. J Am Acad Child Adolesc Psychiatry. 1992 Sep; 31(5):868-74. View abstract
  121. Kaminer Y, Bukstein O, Tarter RE. The Teen-Addiction Severity Index: rationale and reliability. Int J Addict. 1991 Feb; 26(2):219-26. View abstract
  122. Tarter RE, Laird S, Bukstein O. Multivariate comparison of adolescent offspring of substance abuse parents: community and treatment samples. J Subst Abuse. 1991; 3(3):301-6. View abstract
  123. Tarter RE, Laird SB, Kabene M, Bukstein O, Kaminer Y. Drug abuse severity in adolescents is associated with magnitude of deviation in temperament traits. Br J Addict. 1990 Nov; 85(11):1501-4. View abstract
  124. Brent DA, Zelenak JP, Bukstein O, Brown RV. Reliability and validity of the structured interview for personality disorders in adolescents. J Am Acad Child Adolesc Psychiatry. 1990 May; 29(3):349-54. View abstract
  125. Bukstein OG, Brent DA, Kaminer Y. Comorbidity of substance abuse and other psychiatric disorders in adolescents. Am J Psychiatry. 1989 Sep; 146(9):1131-41. View abstract
  126. Kaminer Y, Bukstein O. Adolescent chemical use and dependence: current issues in epidemiology, treatment and prevention. Acta Psychiatr Scand. 1989 May; 79(5):415-24. View abstract
  127. Kaminer Y, Bukstein O, Tarter R. Teen Addiction Severity Index (T-ASI): clinical and research implications: a preliminary report. NIDA Res Monogr. 1989; 95:363. View abstract